{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:43:27Z","timestamp":1794469407840,"version":"4.9.1"},"reference-count":57,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In patients with moderate atopic dermatitis (AD), topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) often do not sufficiently control AD signs\/symptoms, and escalation to systemic therapy may be required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Report 8\u2010week results of ruxolitinib cream in TRuE\u2010AD4 (NCT06238817) in patients with moderate AD who had an inadequate response\/intolerance\/contraindication to TCS and TCI in the past 12\u2009months (post\u2010TCS and \u2010TCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients aged \u226518\u2009years with AD, an Investigator's Global Assessment (IGA) of 3, Eczema Area and Severity Index (EASI) &gt;7, itch numerical rating scale (NRS) \u22654, 10%\u201320% affected body surface area and Dermatology Life Quality Index score &gt;\u200910 post\u2010TCS and \u2010TCI were randomized (2:1) to twice\u2010daily 1.5% ruxolitinib cream or vehicle for 8\u2009weeks. Coprimary endpoints at Week 8 were \u226575% improvement in EASI from baseline (EASI\u201075) and IGA score of 0\/1 with a\u2009\u2265\u20092\u2010point improvement from baseline (IGA treatment success [TS]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 241 randomized patients (mean age, 37.0 y; 54.4% female), mean EASI and itch NRS scores were 12.6 and 7.4, respectively, at baseline. At Week 8, significantly more patients who applied 1.5% ruxolitinib cream versus vehicle achieved IGA\u2010TS (61.3% vs. 13.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and EASI\u201075 (70.0% vs. 18.5%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Significantly more patients achieved a\u2009\u2265\u20094\u2010point improvement in itch NRS (itch NRS4) at Day 2 (29.8% vs. 13.7%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0072); improvement in current itch (no recall) was observed in 15\u2009min after the first application. No treatment\u2010related adverse events were serious, and the most common adverse event occurring with ruxolitinib cream was application site acne (3.8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In adults with moderate AD post\u2010TCS and \u2010TCI, who may otherwise be eligible for systemic therapy, 1.5% ruxolitinib cream significantly improved clinical signs of AD, rapidly improved itch and was well tolerated. Thus, ruxolitinib cream may represent an effective topical option before escalation to systemic therapy in patients with moderate AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70595","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:55:42Z","timestamp":1784534142000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial"],"prefix":"10.1111","author":[{"given":"Jos\u00e9 Manuel","family":"Carrascosa","sequence":"first","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol Universitat Aut\u00f2noma of Barcelona, IGTP  Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"University of Calgary  Calgary Alberta Canada"},{"name":"Dermatology Research Institute  Calgary Alberta Canada"},{"name":"Skin Health &amp; Wellness Centre  Calgary Alberta Canada"},{"name":"Probity Medical Research  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9963-8319","authenticated-orcid":false,"given":"H. Chih\u2010ho","family":"Hong","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"},{"name":"Probity Medical Research  Surrey British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"Royal Wolverhampton NHS Trust  Wolverhampton UK"},{"name":"College of Medicine and Health University of Birmingham  UK"},{"name":"Walsall Healthcare NHS Trust, Walsall  UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[{"name":"Fachklinik Bad Bentheim  Bad Bentheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-632X","authenticated-orcid":false,"given":"Alexander A.","family":"Navarini","sequence":"additional","affiliation":[{"name":"University Hospital of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-6600","authenticated-orcid":false,"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A. Gemelli\u2010IRCCS  Rome Italy"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eingun James","family":"Song","sequence":"additional","affiliation":[{"name":"Frontier Dermatology  Mill Creek Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-399X","authenticated-orcid":false,"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[{"name":"Rosalind Franklin University of Medicine and Science Chicago Medical School  North Chicago Illinois USA"},{"name":"Center for Medical Dermatology + Immunology Research  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6629-9100","authenticated-orcid":false,"given":"S\u00e9bastien","family":"Barbarot","sequence":"additional","affiliation":[{"name":"Nantes Universit\u00e9, Centre Hospitalier Universitaire de Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Popovic","sequence":"additional","affiliation":[{"name":"Incyte Biosciences International S\u00e0rl  Morges Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haq","family":"Nawaz","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Purohit","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[{"name":"University Hospital Augsburg  Augsburg Germany"},{"name":"Comprehensive Center for Inflammation Medicine University of Luebeck  Luebeck Germany"},{"name":"Ludwig\u2010Maximilian University  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16892"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13401"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad339"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01630-z"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.029"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20639"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16046"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.046"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.05.023"},{"issue":"2","key":"e_1_2_13_13_1","first-page":"274","article-title":"Atopic dermatitis (eczema) guidelines: 2023 American Academy of allergy, asthma and immunology\/American College of Allergy, asthma and immunology joint task force on practice parameters GRADE\u2010 and Institute of Medicine\u2010based recommendations","volume":"132","author":"Chu DK","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.006"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.140"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.08.009"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.085"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.09.060"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1385"},{"key":"e_1_2_13_20_1","unstructured":"EichenfieldLF Stein GoldLF SimpsonEL ZaengleinAL ArmstrongAW TollefsonMM et\u00a0al.52\u2010week safety and disease control with ruxolitinib cream in children aged 2\u201311\u2009years with atopic dermatitis: results from the phase 3 TRuE\u2010AD3 study. Presented at: 33rd European Academy of Dermatology and Venereology (EADV) Congress September 25\u201328 2024; Amsterdam The Netherlands."},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","unstructured":"EichenfieldLF SoongW Stein GoldL SimpsonEL BrarKK Wine LeeL et\u00a0al.Efficacy of ruxolitinib cream for the treatment of atopic dermatitis in children aged 2\u201011\u2009years by previous medication history: subgroup analysis from the randomized phase 3 TRuE\u2010AD3 study. Presented at: American Academy of Dermatology March 8\u201012 2024; San Diego CA.","DOI":"10.1016\/j.jaad.2024.07.159"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01272-3"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01219-8"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","unstructured":"EichenfieldLF SimpsonEL ArmstrongAW Stein GoldLF Wine LeeL BrarKK et\u00a0al.52\u2010week disease control and safety with as\u2010needed application of ruxolitinib cream in children aged 2 to 11\u2009years with moderate and\/or more extensive atopic dermatitis: subgroup analysis from the TRuE\u2010AD3 study. Presented at: American Academy of Dermatology Annual Meeting March 7\u201311 2025; Orlando FL USA.","DOI":"10.1016\/j.jaad.2025.05.402"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00690-3"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-024-00909-5"},{"key":"e_1_2_13_27_1","unstructured":"US Food and Drug Administration.FDA requires warnings about increased risk of serious heart\u2010related events cancer blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions.2021. Available from:https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010requires\u2010warnings\u2010about\u2010increased\u2010risk\u2010serious\u2010heart\u2010related\u2010events\u2010cancer\u2010blood\u2010clots\u2010and\u2010death. [Accessed February 2 2024]"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.010"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.054"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0418"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2022.0094"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.05.011"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15641"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00588-2"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206714"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.10.613"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70250"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.159.8.745"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04578.x"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0933"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.12.020"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12590"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18571"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.5243"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2022.9396"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.012"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3830"},{"key":"e_1_2_13_57_1","doi-asserted-by":"crossref","unstructured":"LiuJ DesaiK TengC\u2010C StockbowerG ChenP WilleyV et\u00a0al.Real\u2010world effect of ruxolitinib cream: decreased use of additional topical therapies and limited escalation to systemic treatments. Presented at: Academy of Managed Care Pharmacy Nexus Oct 27\u201330 2025; National Harbor MD USA.","DOI":"10.1007\/s12325-026-03670-9"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01602-z"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T09:41:04Z","timestamp":1786095664000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":57,"alternative-id":["10.1111\/jdv.70595"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70595","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2026-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70595"}}